Pharmacogenomics And The "Learned Intermediary"

Law360, New York (September 26, 2007, 12:00 AM EDT) -- Pharmacogenomics—the notion that drug therapies can be tailored to an individual’s genetic makeup—is one of the great breakthroughs for the pharmaceutical and medical device industries.

It is a research area that promises advances in more effective drug administration by identifying populations for whom certain drugs are likely to be most effective, thereby avoiding unnecessary use of such drugs in populations for whom the drug may not be effective.

Moreover, pharmacogenomics may help address certain safety concerns if healthcare providers can look at genetic data to identify...
To view the full article, register now.